Filtered By:
Infectious Disease: Coronavirus
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 524 results found since Jan 2013.
RNA nanotechnology: A new chapter in targeted therapy
Colloids Surf B Biointerfaces. 2023 Sep 6;230:113533. doi: 10.1016/j.colsurfb.2023.113533. Online ahead of print.ABSTRACTNanoparticles have been widely studied in the fields of biotechnology, pharmacy, optics and medicine and have broad application prospects. Numerous studies have shown significant interest in utilizing nanoparticles for chemically coating or coupling drugs, aiming to address the challenges of drug delivery, including degradability and uncertainty. Furthermore, the utilization of lipid nanoparticles loaded with novel coronavirus antigen mRNA to control the COVID-19 pandemic has led to a notable surge in re...
Source: Colloids and Surfaces - September 15, 2023 Category: Biotechnology Authors: Tongtong Lv Yingying Meng Yifan Liu Yukun Han Hongwu Xin Xiaochun Peng Jinbai Huang Source Type: research
Stimuli-Responsive Hydrogel Microcapsules Harnessing the COVID-19 Immune Response for Cancer Therapeutics
We present the development of stimuli-responsive microcapsules, loaded with a viral immunogenetic agent, harnessing the immune response against the Coronavirus Disease 2019, COVID-19, to selectively attack liver cancer cells (hepatoma) or recognize breast cancer or hepatoma, by expression of green fluorescence protein, GFP. The pH-responsive microcapsules, modified with DNA-tetrahedra nanostructures, increased hepatoma permeation by 50%. Incorporation of a GFP-encoding lentivirus vector inside the tumor-targeting pH-stimulated miRNA-triggered and Alpha-fetoprotein-dictated microcapsules enables the demonstration of neoplas...
Source: Angewandte Chemie - September 7, 2023 Category: Chemistry Authors: Amit Fischer Avner Ehrlich Yevgeni Plotkin Yu Ouyang Klil Asulin Ioannidis Konstantinos Chunhai Fan Yaakov Nahmias Itamar Willner Source Type: research
Patient Report on the Impact of Coronavirus Disease 2019 and Living With Lung Cancer
CONCLUSIONS: An integrative patient-reported view on the impact of COVID-19 is important for adequate preparation to ensure undisrupted treatment and allocation of resources.PMID:37663676 | PMC:PMC10472288 | DOI:10.1016/j.jtocrr.2023.100549
Source: Clinical Lung Cancer - September 4, 2023 Category: Cancer & Oncology Authors: Tendai M Chihuri Upal Basu Roy Amy Moore Anne-Marie Baird Tracey L Grant Bellinda L King-Kallimanis Source Type: research
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
Blood Cancer J. 2023 Aug 1;13(1):116. doi: 10.1038/s41408-023-00879-7.ABSTRACTBispecific antibodies (BsAbs) are emerging as an important novel class of immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to be more widely used in clinical practice. However, this new class of therapies is associated with a distinct adverse event (AE) profile that includes cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, as well as AEs leading to increased infection risk such as cytopenias and hypogammaglobulinemia, and infections themselves. As preliminary data with this clas...
Source: Herpes - August 1, 2023 Category: Infectious Diseases Authors: Noopur Raje Kenneth Anderson Hermann Einsele Yvonne Efebera Francesca Gay Sarah P Hammond Alexander M Lesokhin Sagar Lonial Heinz Ludwig Philippe Moreau Krina Patel Karthik Ramasamy Maria-Victoria Mateos Source Type: research
Impact of an autophagy-inducing peptide on immunogenicity and protection efficacy of an adenovirus-vectored SARS-CoV-2 vaccine
Mol Ther Methods Clin Dev. 2023 Jun 27;30:194-207. doi: 10.1016/j.omtm.2023.06.009. eCollection 2023 Sep 14.ABSTRACTBecause of continual generation of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it is critical to design the next generation of vaccines to combat the threat posed by SARS-CoV-2 variants. We developed human adenovirus (HAd) vector-based vaccines (HAd-Spike/C5 and HAd-Spike) that express the whole Spike (S) protein of SARS-CoV-2 with or without autophagy-inducing peptide C5 (AIP-C5), respectively. Mice or golden Syrian hamsters immunized intranasally (i.n.) with HAd-Spike/C5 in...
Source: Clinical Lung Cancer - July 28, 2023 Category: Cancer & Oncology Authors: Ekramy E Sayedahmed Marcelo Valdemir Ara újo Taiana Tain á Silva-Pereira Shubhada K Chothe Ahmed Elkashif Marwa Alhashimi Wen-Chien Wang Andrea P Santos Meera Surendran Nair Abhinay Gontu Ruth Nissly Ant ônio Francisco de Souza Filho Mariana Silva Tava Source Type: research
COVID-19 Antibody Response in Patients with Thalassemia
Conclusion Patients with TDT manifest with mild or asymptomatic COVID-19 and mount a comparable IgG antibody response to COVID-19 akin to controls. However, this serological response could not sustain over three to six months advocating the need for protection through vaccination.PMID:37465812 | PMC:PMC10351617 | DOI:10.7759/cureus.40567
Source: Cancer Control - July 19, 2023 Category: Cancer & Oncology Authors: Nidhi Kumari Sunil Gomber Pooja Dewan Shiva Narang Rafat Ahmed Source Type: research
Increased neutralization potency and breadth elicited by a SARS-CoV-2 mRNA vaccine forming virus-like particles
Proc Natl Acad Sci U S A. 2023 Jul 18;120(29):e2305896120. doi: 10.1073/pnas.2305896120. Epub 2023 Jul 10.ABSTRACTVaccines have played a fundamental role in the control of infectious diseases. We previously developed a messenger RNA (mRNA) vaccine against HIV-1 that forms virus-like particles (VLPs) through coexpression of the viral envelope with Gag. Here, we applied the same principle to the design of a VLP-forming mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To promote cognate interaction with simian immunodeficiency virus (SIV) Gag, we engineered different chimeric proteins encompa...
Source: Cancer Control - July 10, 2023 Category: Cancer & Oncology Authors: Peng Zhang Samantha Falcone Yaroslav Tsybovsky Mamta Singh Vinay Gopan Huiyi Miao Yuna Seo Denise Rogers Isabella Renzi Yen-Ting Lai Elisabeth Narayanan Guillaume Stewart-Jones Sunny Himansu Andrea Carfi Anthony S Fauci Paolo Lusso Source Type: research
Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors
CONCLUSIONS: Our findings would strengthen the recommendation not to change anti-PD-1/PD-L1 treatment plans based on current or future immunization schedules, implying that all these patients should be closely monitored.PMID:37428196 | DOI:10.1007/s00262-023-03489-1
Source: Cancer Control - July 10, 2023 Category: Cancer & Oncology Authors: Fabrizio Nelli Diana Giannarelli Agnese Fabbri Antonella Virtuoso Julio Rodrigo Giron Berrios Eleonora Marrucci Cristina Fiore Marta Schirripa Carlo Signorelli Mario Giovanni Chilelli Francesca Primi Valentina Panichi Giuseppe Topini Maria Assunta Silvest Source Type: research
High SARS-CoV-2 seroprevalence in Lagos, Nigeria with robust antibody and cellular immune responses
CONCLUSIONS: These results have important implications for understanding the paradoxically high SARS-CoV-2 infection with low mortality rate in Africa and supports the need to better understand the implications of SARS-CoV-2 cellular immunity.PMID:37388808 | PMC:PMC10289822 | DOI:10.1016/j.jcvp.2023.100156
Source: Cancer Control - June 30, 2023 Category: Cancer & Oncology Authors: Sulaimon Akanmu Bobby Brooke Herrera Beth Chaplin Sade Ogunsola Akin Osibogun Fatima Onawoga Sarah John-Olabode Iorhen E Akase Augustina Nwosu Donald J Hamel Charlotte A Chang Phyllis J Kanki Source Type: research
Anthracyclines inhibit SARS-CoV-2 infection
Virus Res. 2023 Jun 26:199164. doi: 10.1016/j.virusres.2023.199164. Online ahead of print.ABSTRACTVaccines and drugs are two effective medical interventions to mitigate SARS-CoV-2 infection. Three SARS-CoV-2 inhibitors, remdesivir, paxlovid, and molnupiravir, have been approved for treating COVID-19 patients, but more are needed, because each drug has its limitation of usage and SARS-CoV-2 constantly develops drug resistance mutations. In addition, SARS-CoV-2 drugs have the potential to be repurposed to inhibit new human coronaviruses, thus help to prepare for future coronavirus outbreaks. We have screened a library of mic...
Source: Virus Research - June 28, 2023 Category: Virology Authors: Zhen Wang Qinghua Pan Ling Ma Jianyuan Zhao Fiona McIntosh Zhenlong Liu Shilei Ding Rongtuan Lin Shan Chen Andr és Finzi Chen Liang Source Type: research
